"Devyser reported another quarter of strong organic growth, which again saw record-breaking sales. The gross margin remained high. Both sales and margins have the potential for further improvement as we move forward with the transition from distributor sales to direct sales.
Sales for the quarter amounted to
Fredrik Alpsten, CEO, Devyser
Quarter April-
- Net sales amounted to
SEK 30.9 million (21.8), corresponding to a 41.5% increase. Adjusted for exchange rate fluctuations, net sales increased by 36.2%. -
Gross profit totaled
SEK 24.7 million (16.2), corresponding to a gross margin of 79.9% (74.0). -
Operating profit (EBIT) amounted to
SEK -12.6 million (-5.5). -
Profit after tax totaled
SEK -14.3 million (-6.2). -
Earnings per share before and after dilution amounted to
SEK -0.90 (-0.55). -
Cash flow from operating activities stood at
SEK -7.9 million (-12.4).
The period from January to
- Net sales amounted to
SEK 61.3 million (44.6), corresponding to a 37.2% increase. Adjusted for exchange rate fluctuations, net sales increased by 32.4%. -
Gross profit totaled
SEK 49.9 million (34.3), corresponding to a gross margin of 81.4% (77.0). -
Operating profit (EBIT) amounted to
SEK -17.9 million (-4.8). -
Profit after tax totaled
SEK -20.4 million (-6.5). -
Earnings per share before and after dilution amounted to
SEK -1.29 (-0.61). -
Cash flow from operating activities stood at
SEK -15.3 million (-7.4).
Important events during the quarter
Annual General Meeting
At the Annual General Meeting in May, Mia Arnhult, Lars Höckenström,
Breakthrough contract in
In June, Devyser won a contract with Héma-
Strengthening of the management team
In June,
New share issues
In April, a new share issue totaling 62,400 shares was carried out in connection with the exercising of warrants. This raised
Important events after the end of the quarter
In September,
After the balance sheet date, two new share issues were completed in connection with the exercising of warrants, and at the time of submission of this report the number of shares was 16,006,369.
The report is available on the company's webpage:
https://investors.devyser.com/en/reports-presentations
This information is information that
For more information, please contact:
Fredrik Alpsten, CEO
E-mail: fredrik.alpsten@devyser.com
Tel: +46 706 673 106
E-mail: sabina.berlin@devyser.com
Tel: +46 739 519 502
About
Devyser develops, produces, and commercializes genetic test kits for laboratories in more than 45 countries. The products are used for advanced DNA testing within hereditary diseases, oncology, and transplantation to guide targeted cancer therapies, diagnose a wide array of genetic diseases, and to assist in post-transplant follow-up. Devyser's products simplify complex genetic testing processes, minimize hands-on time and deliver rapid, accurate, and trusted results. Devyser was founded in 2004 and is based in
Devyser's shares are listed on Nasdaq First North Growth Market (ticker: DVYSR). The company's certified adviser is
https://news.cision.com/devyser-diagnostics-ab/r/devyser-diagnostics-ab-publishes-interim-report-for-the-period--january-to-june-2022,c3618587
https://mb.cision.com/Main/13649/3618587/1617988.pdf
(c) 2022 Cision. All rights reserved., source